UniServices Executive Leadership Team
PhD. For the first ten years of Andy's career he was an academic at the University of Delaware, Yale University and U.C. Irvine before joining New Zealand company Genesis Research and Development Corporation Ltd. After seven years in research and senior management positions at Genesis, Andy moved to Fonterra where he held a variety of senior positions in research strategy, venture investment and most recently as Chief Scientist.
During his time at Fonterra, Andy was a Director and Chairman of Lactopharma, a joint venture company owned by Fonterra and Auckland UniServices Ltd, and he served as Fonterra's Board representative on a number of new spin-out companies. Andy holds a BSc in Biology from Rhodes College and a PhD in Biological Sciences from the University of Delaware.
Ian Olan was appointed COO in July 2018, he holds full operational responsibility for Business & Information Systems, Finance, Funds & Submissions, Research Portfolio Management, Contract Management, People & Culture, Business Intelligence, and Communications & Marketing. Previously, Ian has held senior positions in Finance, Operations, Governance and Transformation with companies in New Zealand and abroad including: PwC, Lear Corporation, Johnson Controls, Fonterra, BNZ, ADHB, F&P Healthcare and Fletcher Building. Ian has a Master of Business Administration from Benemérita Universidad Autónoma de Puebla, Bachelor’s in Accounting and a Postgrad in Auditing with the same University. Ian is a Fellow of CPA Australia, PMP, MInstD and Certified Six Sigma Black Belt from the American Society for Quality where he has been a senior member for a decade. Ian has been the recipient of: CONACYT/CECYT scholarship for his MBA thesis ‘Implementing Cost of Quality within manufacturing sector’, Healthcare excellence awards 2011 including publishing in BJA, CFO awards 2015.
Will Charles has been General Manager Commercialisation since 2005. During this time UniServices has transacted over 185 licensing deals, started 31 companies and raised over $80 million in venture and seed funding for these companies, and has successfully exited a number of these.
He set up the TransTasman Commercialisation Fund, a A$30 million seed fund with four Australian Universities and sat on the Investment Committee of the fund. He is a director of a number of start-up companies. He also set up and is responsible for the direction of Return on Science which is part of the Ministry of Business, Innovation and Economic Development’s Commercialisation Partner Network. He has been a speaker at a number of international Technology Transfer events including the Association of Technology Managers in the US (AUTM) and BioEurope.
Previously, Will has had extensive senior commercial experience in businesses in Europe, Asia and New Zealand where he has held executive positions at a number of companies including Novartis, GlaxoSmithKline, Roche, Celltech and Wolters Kluwer.